Antiprogrammed Cell Death‐1 Immunotherapy‐Related Secondary Sclerosing Cholangitis
Sign Up to like & getrecommendations! Published in 2019 at "Hepatology"
DOI: 10.1002/hep.30189
Abstract: Secondary sclerosing cholangitis (SSC) is a rare disease that is associated with various etiologies. Recent development of immune checkpoint inhibitors demonstrates efficacy in the treatment of various malignancies; however, these inhibitors can also cause immune-related… read more here.
Keywords: antiprogrammed cell; cell death; secondary sclerosing; sclerosing cholangitis ... See more keywords
Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Sign Up to like & getrecommendations! Published in 2020 at "Neurosurgery"
DOI: 10.1093/neuros/nyaa421
Abstract: BACKGROUND The lack of immune synergy with conventional chemoradiation could explain the failure of checkpoint inhibitors in current clinical trials for high-grade gliomas (HGGs). OBJECTIVE To analyze the impact of radiotherapy (RT), Temozolomide (TMZ) and… read more here.
Keywords: high grade; radiotherapy temozolomide; immune microenvironment; tmz ... See more keywords
Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice
Sign Up to like & getrecommendations! Published in 2018 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758835918768238
Abstract: Background: The emergence of novel antiprogrammed cell death protein-1 (PD-1) inhibitors in non-small cell lung cancers (NSCLC) has revolutionized the therapeutic landscape of this disease. Although overall survival (OS) has improved in the first- and… read more here.
Keywords: death protein; cell death; antiprogrammed cell; non small ... See more keywords